Comvax

What is Comvax

Comvax is a bivalent vaccine made up of the antigenic components present in PedvaxHIB (Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate)) and Recombivax HB (hepatitis B vaccine, recombinant).

Comvax is indicated for vaccination against invasive disease caused by Haemophilus influenzae type b and against infection caused by all known subtypes of hepatitis B virus in infants 6 weeks to 15 months of age born of HBsAg negative mothers.

The combination provides a convenient dosage form for infants who are scheduled to receive both vaccines at the same time. A 3-dose primary immunization series is required.

Indications

  1. Haemophilus influenzae type b prophylaxis
  2. hepatitis B prophylaxis

Side Effects

  1. anaphylactoid reactions
  2. angioedema
  3. anorexia
  4. candidiasis
  5. cough
  6. diarrhea
  7. drowsiness
  8. erythema
  9. erythema multiforme
  10. fever
  11. Guillain-Barre syndrome
  12. inconsolable crying
  13. infection
  14. injection site reaction
  15. irritability
  16. nasal congestion
  17. rash
  18. rhinorrhea
  19. seizures
  20. Stevens-Johnson syndrome
  21. thrombocytopenia
  22. urticaria
  23. vomiting

Monitoring Parameters

  • laboratory monitoring not necessary

Contraindications

  • agammaglobulinemia
  • anticoagulant therapy
  • breast-feeding
  • children
  • coagulopathy
  • corticosteroid therapy
  • fever
  • geriatric
  • hemophilia
  • human immunodeficiency virus (HIV) infection
  • hypogammaglobulinemia
  • immunosuppression
  • infants
  • infection
  • intravenous administration
  • latex hypersensitivity
  • neonates
  • neoplastic disease
  • pregnancy
  • radiation therapy
  • severe combined immunodeficiency (SCID)
  • subcutaneous administration
  • thrombocytopenia
  • vitamin K deficiency
  • yeast hypersensitivity

Interactions

  • Hepatitis B Immune Globulin, HBIG
  • Ocrelizumab
  • Siponimod
You cannot copy content of this page